Powerful.
Dexcom G6 is the first real-time, integrated CGM (iCGM) for patients ages 2 years and older. Zero fingersticks* or scanning required.
*If your glucose alerts and readings from Dexcom G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.
Proven.
Dexcom CGM use is clinically proven to lower A1C, reduce hyper- and hypoglycemia, and increase time in range.3,4
Protective.
A suite of alerts and a fixed Urgent Low alarm can help warn patients of high or low glucose levels.
Zero fingersticks* and
scanning, at zero cost.†
Prescribe a no-cost sample of the Dexcom G6
Continuous Glucose Monitoring (CGM) System for your
patients with diabetes. Greater accessibility and coverage
make it easier to get them started than ever before.
Hello Dexcom is a no-cost sampling program that helps introduce the features and benefits of Dexcom G6.
One third of patients pay $0 out of pocket at the pharmacy for their Dexcom G6.‡,5
Three out of four patients on mealtime insulin have pharmacy coverage for the Dexcom G6 CGM System.6
Dexcom integrations with diabetes
technology collaborators
As the first Class II integrated CGM (iCGM) authorized by the FDA, Dexcom G6 is cleared to work interoperably with a range of connected insulin pen and closed loop system partners. We continue to pursue collaboration opportunities with product and digital health brands, offering a multifaceted approach to effective diabetes management for patients, caregivers, and healthcare providers.
Dexcom is proud to team up with the following product companies to develop new diabetes treatment platforms and integrations, in support of more customizable and convenient treatment options.
Through Digital Health Partnerships, Dexcom empowers its users and providers to view their glucose data in the system of their choice, with the aim of satisfying user demand for app-based care. Users authorize third-party apps to connect to their data through the Dexcom cloud, extending the power of Dexcom CGM.
Dexcom is proud to support and work with the following non-profit organizations to help reduce the financial, emotional, and social burden of diabetes that affects many patients.
Clinical Evidence
A wide body of evidence substantiates the efficacy of Dexcom CGM. Take a deeper dive into the research that speaks to its benefits by reviewing the novel DIaMonD Study and other relevant materials.
Featured Resources
DIaMonD Study1 shows that Dexcom CGM use improves glucose control in adults with type 1 diabetes using insulin injections.
Learn how to prescribe Dexcom G6 through the Dexcom Start program, a simpler prescribing process for you and your patients. The first prescription should include three items: 1 receiver, 1 wireless...
Provide patient care anywhere with this collection of telehealth tools and resources. Access our collection of guides for healthcare providers who are remotely meeting with Dexcom patients.
†Patient must have a Dexcom G6 prescription and a compatible smart device (sold separately) as part of this 10-day experience: dexcom.com/compatibility. Dexcom G6 can be provided at no cost for the sole purpose of allowing a healthcare provider and/or patient to evaluate if Dexcom G6 is right for the patient. All recipients of this pack are strictly prohibited from collecting any compensation related to it. This offer is void where prohibited by law. Dexcom may modify or rescind this offer at any time without notice. For the complete version of the terms and conditions, please visit dexcomprovider.com/hello.
‡Refers to the estimated out-of-pocket cost for eligible commercially insured patients for the Dexcom G6 sensor and transmitter when claims are adjudicated as a pharmacy benefit, and includes benefits and offerings through available Dexcom programs, such as the voucher program. Actual cost may vary and is subject to individual insurance coverage.
§Represents the percentage of patients who completed their 10-day Dexcom G6 wear session.
1 Shah VN, et al. Diabetes Technol Ther. 2018;20(6): 428-433.
2 Seagrove Partners Q3 2020 Patient Perspectives Survey. 2020: 36.
3 Beck, RW, et al. JAMA. 2017;317(4):371-378.
4 Welsh, J.B. et al. Diabetes Technol Ther. 2019;21(3): 128-132.
5 Dexcom, data on file. Oct. 2020-March 2021.
6 Dexcom, data on file. 2020